Cell-type selectivity can be achieved by deleting the natural receptor binding capacity of PA63 by single amino acid exchange in its B-domain (mPA63) and fusing peptide ligands for receptors on the surface of certain cancer cells such as EGF or ZHER2, the ligand for HER2 receptor. Here, EGF is linked to cancer.